Growing concerns about clinical autonomy, competition, and patient access spurred states to increasingly enact legislation targeted at private equity investment in health care last year. The new year will likely bring more deals subject to state review, tighter regulatory guardrails, and increased scrutiny of highly leveraged transactions and serial acquisitions consolidating multiple medical practices. Ultimately, transactions that credibly safeguard clinical independence, maintain sustainable financing, and deliver demonstrable gains in access and outcomes will be best positioned for state approval and durable performance.
Read the full article: Growing Health-Care, Private Equity Scrutiny Shadows 2026 Deals //
Source: https://news.bloomberglaw.com/legal-exchange-insights-and-commentary/growing-health-care-private-equity-scrutiny-shadows-2026-deals